Drug Trial Radar · NCT00410384
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Feb 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
819
Actual
Start
Dec 2006
Primary completion
Sep 2009
Study completion Mar 2010
Sponsor
- Lead sponsor
- Human Genome Sciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Dec 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
Conditions
- Systemic Lupus Erythematosus
Interventions
PlaceboDrug
Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Belimumab 1 mg/kgDrug
Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Belimumab 10 mg/kgDrug
Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SLE Responder Index (SRI) Response Rate at Week 52Time frame: Baseline, 52 Weeks
Locations
146 sites in 19 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Arthritis and Rheumatology Research, PPLC
Paradise Valley, Arizona
The University of Arizona Arthritis Center
Tucson, Arizona
Talbert Medical Group
Huntington Beach, California
Valerius Medical Group & Research Ctr of Greater Long Beach, Inc.
Long Beach, California
University of Southern California
Los Angeles, California
Wallace Rheumatic Study Center
Los Angeles, California
UCLA Rheumatology
Los Angeles, California
Arthritis Care Center, Inc.
San Jose, California
Inland Rheumatic Disease Specialties
Upland, California
Arthritis Associates of Colorado Springs
Colorado Springs, Colorado
Washington Hospital Center
Washington D.C., District of Columbia
Arthritis and Rheumatic Disease Specialties
Aventura, Florida
University of Miami-Division of Rheumatology and Immunology
Miami, Florida
Rheumatology Associates of Central Florida
Orlando, Florida
Southwest Florida Clinical Research Center
Tampa, Florida
Tampa Medical Group, P.A.
Tampa, Florida
Emory University
Atlanta, Georgia
Selah Medical Clinical Research Unit
Boise, Idaho
Rheumatology Associates, SC
Chicago, Illinois
University of Chicago Hospitals
Chicago, Illinois
Medical Specialists Clinical Research
Munster, Indiana
Kansas University Medical Center
Kansas City, Kansas
Kentuckiana Center for Better Bone and Joint Health
Louisville, Kentucky
Ochsner Clinic Foundation
Baton Rouge, Louisiana
Johns Hopkins University
Baltimore, Maryland
Osteoporosis and Clinical Trials Center
Cumberland, Maryland
Osteoporosis & Clinical Trials Center
Hagerstown, Maryland
Tufts - New England Medical Center
Boston, Massachusetts
University of Michigan Medical Center - Regents of University of Michigan
Ann Arbor, Michigan
Fiechtner Research, Inc.
Lansing, Michigan
Washington University School of Medicine
St Louis, Missouri
Stafford Medical Associates, PA
Dover, New Hampshire
SUNY-Downstate Medical Center
Brooklyn, New York
North Shore-LIJ Health System/Rheumatology and Allergy Clinic
Lake Success, New York
Feinstein Institute
Manhasset, New York
Hopital for Joint Diseases
New York, New York
Hospital for Special Surgery
New York, New York
AAIR Research Center
Rochester, New York
Rheumatology Associates
Smithtown, New York
Showing 40 of 146 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.